BRAF and melanoma: Regardless of BRAF V600E mutational status, virtually all melanomas have activity in the MAPK pathway (Satyamoorthy et al, 2003), and this contributes to the oncogenic phenotype of melanoma through its effects on cell proliferation, invasion and survival (Gray-Schopfer et al, 2007).